Heart risk from diabetes drug Actos as great as from Avandia, study finds - latimes.com

Links shared publicly online about this topic.

923
total visits

Heart risk from diabetes drug Actos as great as from Avandia, study finds - latimes.com

The continuing controversy surrounding the cardiovascular risk of the diabetes drug Avandia has led to sharp declines in its use and a surge in sales of the competing drug Actos, in part because the latter is perceived to be safer. Sales of Avandia, as high as $3.4 billion in 2006, have fallen to about $1.1 billion this year, while those of Actos have climbed to about $4.6 billion. But new results reported Monday suggest that the cardiovascular risks of the two drugs are about the same.

View full resource at latimes.com

Tags: Heart, Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Drug, Actos